26.04
+0.21(+0.81%)
Currency In USD
Address
2656 State Street
Carlsbad, CA 92008
United States of America
Phone
619 728 4760
Website
Sector
Healthcare
Industry
Biotechnology
Employees
60
First IPO Date
September 15, 2021
| Name | Title | Pay | Year Born |
| Todd Harris | Co-Founder, President, Chief Executive Officer, Secretary, Treasurer & Director | 1.07M | 1979 |
| Ronald V. Swanson | Chief Scientific Officer | 536,188 | 1963 |
| Douglas Warner | Chief Medical Officer | 627,900 | 1972 |
| Ali D. Fawaz | General Counsel | 629,230 | N/A |
| Daniel Bensen | Co-Founder & Chief Discovery Officer | 737,643 | 1975 |
| Alan Fuhrman | Chief Financial Officer | 763,093 | 1957 |
| Piyush R. Patel | Chief Development Officer | 0 | 1965 |
| Robert L. Hudkins | Chief Technology Officer | 0 | 1955 |
| Liz Pagano | Senior Vice President of Human Resources | 0 | N/A |
| Bhavesh Ashar | Chief Operating Officer | 0 | 1966 |
| Sarah Honig | Senior Vice President of Corporate Development & Strategy | 0 | N/A |
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
